Related references
Note: Only part of the references are listed.CYP2D6-and CYP3A-Dependent Enantioselective Plasma Concentrations of Ondansetron in Postanesthesia Care
Ulrike M. Stamer et al.
ANESTHESIA AND ANALGESIA (2011)
Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone A Randomized, Three-Phase, Crossover, Placebo-Controlled Study
Juha Gronlund et al.
CLINICAL DRUG INVESTIGATION (2011)
Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CYP3A5*3 Affects Plasma Disposition of Noroxycodone and Dose Escalation in Cancer Patients Receiving Oxycodone
Takafumi Naito et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia
S. T. Zwisler et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2010)
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
C. F. Samer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
C. F. Samer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
Teijo I. Saari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone
Juha Gronlund et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
K. K. Lemberg et al.
SCANDINAVIAN JOURNAL OF PAIN (2010)
A Comparison of Intravenous Oxycodone and Intravenous Morphine in Patient-Controlled Postoperative Analgesia After Laparoscopic Hysterectomy
Harald Lenz et al.
ANESTHESIA AND ANALGESIA (2009)
Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone
Tuija H. Nieminen et al.
ANESTHESIOLOGY (2009)
The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism
Stine T. Zwisler et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Voriconazole drastically increases exposure to oral oxycodone
Nora M. Hagelberg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid?
Kim K. Lemberg et al.
SCANDINAVIAN JOURNAL OF PAIN (2009)
CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients
Severine Crettol et al.
THERAPEUTIC DRUG MONITORING (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
Magnus Ingelman-Sundberg et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes
U. M. Stamer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Antinociception by spinal and systemic oxycodone:: Why does the route make a difference?: In vitro and in vivo studies in rats
Kim K. Lemberg et al.
ANESTHESIOLOGY (2006)
Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
Margaret T. Susce et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites
F. Musshoff et al.
JOURNAL OF MASS SPECTROMETRY (2006)
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Bojan Lalovic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Clinical implications of CYP3A polymorphisms
Leszek Wojnowski et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats
EM Peckham et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Activation of G-proteins by morphine and codeine congeners:: Insights to the relevance of O- and N-demethylated metabolites at μ- and δ-opioid receptors
CM Thompson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
J de Leon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design
CC Apfel et al.
BRITISH JOURNAL OF ANAESTHESIA (2002)
Share Paper
